Literature DB >> 1726404

Teratogenicity of Ni2+ in Xenopus laevis, assayed by the FETAX procedure.

S M Hopfer1, M C Plowman, K R Sweeney, J A Bantle, F W Sunderman.   

Abstract

The teratogenicity of Ni2+ was tested by the FETAX (Frog Embryo Teratogenesis Assay: Xenopus) procedure in the South African frog, Xenopus laevis. In seven assays, beginning at 5 h postfertilization, groups of Xenopus embryos were incubated for 96 h in media that contained Ni2+ (added as NiCl2) at concentrations ranging from 1 x 10(-7) to 3 x 10(-3) mol/L; control groups were incubated in the same medium without added NiCl2. At 101 h postfertilization, surviving embryos were counted, fixed in formalin, and examined by microscopy to determine their developmental stages, malformations, and head-to-tail lengths. In control embryos, survival was greater than or equal to 95% and malformations were less than or equal to 7%. Malformations were found in greater than 95% of embryos exposed to Ni2+ concentrations greater than or equal to 5.6 mumol/L. The most frequent malformations in Ni(2+)-exposed embryos were ocular, skeletal, and intestinal deformities; less common malformations included facial, cardiac, and integumentary deformities. Other abnormalities, not categorized as malformations, included stunted growth, dermal hypopigmentation, and coelomic effusions or hemorrhages. The median embryolethal concentration (LC50) of Ni2+ was 365 (SE +/- 9) mumol/L; the median teratogenic concentration (EC50) was 2.5 (SE +/- 0.1) mumol/L; the Teratogenic Index (TI = LC50/EC50) was 147 (SE +/- 5), indicating that Ni2+ is a potent teratogen for Xenopus laevis. Experiments in which Ni(2+)-exposures were limited to specific 24 h periods showed that Xenopus embryos were most susceptible to Ni(2+)-induced malformations on the second and third days of life, during the most active period of organogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726404     DOI: 10.1007/bf03032678

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  32 in total

1.  Eye malformations in rats: induction by prenatal exposure to nickel carbonyl.

Authors:  F W Sunderman; P R Allpass; J M Mitchell; R C Baselt; D M Albert
Journal:  Science       Date:  1979-02-09       Impact factor: 47.728

2.  The effects of metals on the chick embryo: toxicity and production of abnormalities in development.

Authors:  L P RIDGWAY; D A KARNOFSKY
Journal:  Ann N Y Acad Sci       Date:  1952-08-08       Impact factor: 5.691

3.  Where have all the froggies gone?

Authors:  M Barinaga
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

4.  The metabolism of nickel-63 carbonyl.

Authors:  F W Sunderman; C E Selin
Journal:  Toxicol Appl Pharmacol       Date:  1968-03       Impact factor: 4.219

5.  [Embryotoxic effect of nickel entering the body via drinking water].

Authors:  V G Nadeenko; V G Lenchenko; T A Arkhipenko; S P Saĭchenko; N N Petrova
Journal:  Gig Sanit       Date:  1979-06

6.  Placental transfer and body distribution of nickel chloride in pregnant mice.

Authors:  C C Lu; N Matsumoto; S Iijima
Journal:  Toxicol Appl Pharmacol       Date:  1981-07       Impact factor: 4.219

7.  Teratogenic effects of nickel chloride on embryonic mice and its transfer to embryonic mice.

Authors:  C C Lu; N Matsumoto; S Iijima
Journal:  Teratology       Date:  1979-04

8.  Protein blotting method for detection of nickel-binding proteins.

Authors:  S M Lin; S M Hopfer; S M Brennan; F W Sunderman
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1989-09

9.  Ethene (ethylene) and ethane exhalation in Ni[II]-treated rats, using an improved rebreathing apparatus.

Authors:  J A Knight; S M Hopfer; M C Reid; S H Wong; F W Sunderman
Journal:  Ann Clin Lab Sci       Date:  1986 Sep-Oct       Impact factor: 1.256

10.  Effect of nickel chloride and cadmium acetate on the development of preimplantation mouse embryos in vitro.

Authors:  R Storeng; J Jonsen
Journal:  Toxicology       Date:  1980       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.